Best Direct Primary Care GLP-1 Providers in 2026 — Ranked & Reviewed
Direct Primary Care (DPC) is a membership-based primary-care model that strips out insurance billing and replaces it with a flat monthly fee. A small but growing group of DPC practices have added GLP-1 weight-loss medication to the membership at wholesale or near-wholesale cost — fundamentally different from the DTC marketplace pattern where you pay $300-$500/month for the medication and have no continuous primary-care relationship. The DPC model integrates lab monitoring, medication adjustments, and side-effect management within an ongoing provider relationship, which most clinicians consider the gold standard for chronic-weight-management care. Membership fees typically run $50-$150/month; wholesale GLP-1 then runs $65-$300/month depending on drug, dose, and form. For patients without insurance coverage of brand-name Wegovy/Zepbound, DPC can be the lowest total-cost path to GLP-1 plus comprehensive care.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
How we rank & what counts as “legit”
Every provider in this ranking is scored against our published six-factor rubric[1] — value, effectiveness, user experience, trust & safety, accessibility, and support.
Brand-name Wegovy, Zepbound, Ozempic, and Mounjaro are separately FDA-approved under their own NDA numbers[4][5]. Published Phase 3 efficacy for semaglutide 2.4 mg (~14.9% mean weight loss over 68 weeks) comes from the STEP 1 trial[6], and for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) from SURMOUNT-1[7]; the SURMOUNT-5 head-to-head published in 2025 compared the two directly[8].
Insurance coverage for anti-obesity medications varies widely by state Medicaid program and commercial plan[9][10]. Compounded and brand-name GLP-1s are generally FSA/HSA eligible with a prescription under IRS Publication 502[11].
Quick Picks: Top 1
| # | Provider | Score | |
|---|---|---|---|
| 1 | Primary Clinic (Direct GLP) | 8.0 | Visit |
Detailed Reviews
Primary Clinic (Direct GLP)
Best for: GLP-1 at wholesale cost inside a Direct Primary Care membership
Primary Clinic (Direct GLP) is a Direct Primary Care membership rather than the usual direct-to-consumer GLP-1 marketplace. For $89/mo members get unlimited primary care, direct text access, same-day virtual visits and routine labs — then buy compounded 503A GLP-1s at wholesale with no markup: semaglutide from $65/mo, tirzepatide from $110/mo. Currently available in 10 states, with medication monitoring built into an ongoing care relationship.
Score Breakdown
Pros
- ✓Direct Primary Care model integrates GLP-1 with continuous primary care — unlike most direct-to-consumer platforms
- ✓GLP-1 at wholesale cost with no markup — semaglutide from $65/mo, tirzepatide from $110/mo (members only)
- ✓Unlimited primary care visits, direct text access, and same-day care bundled in the $89/mo membership
- ✓Routine labs and thousands of medications included in membership — no surprise bills
- ✓Per-dose pricing shown publicly for all 8 dose tiers of both semaglutide and tirzepatide
- ✓Publishes the FDA 503A compounded-medication disclaimer
Cons
- ✗10 states only (WA, NM, AZ, UT, FL, DC, KS, OK, VA, GA) — limited vs 50-state platforms
- ✗Membership required to access wholesale pricing — $89/mo adds ~$1,068/yr in fixed cost
- ✗503A pharmacy partners not named
- ✗LegitScript certification not mentioned on the site
- ✗Medical director and corporate legal entity not disclosed
- ✗Compounded only — no brand-name Wegovy, Ozempic, Mounjaro, or Zepbound
- ✗Refund policy not disclosed publicly
Related Rankings
Frequently Asked Questions
Sources & methodology — as of July 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
- 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
- 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.